Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Docolic is a pediatric combination medication developed and marketed by Yash Pharma Laboratories for the symptomatic relief of infantile colic and gastrointestinal spasms. It contains two active pharmaceutical ingredients: dicyclomine hydrochloride and simethicone. Dicyclomine hydrochloride is an antispasmodic agent that functions as a muscarinic acetylcholine receptor antagonist, effectively relaxing smooth muscle in the gastrointestinal tract to alleviate cramping. Simethicone is an anti-flatulent surfactant that reduces the surface tension of gas bubbles in the stomach and intestines, facilitating their coalescence and expulsion. Formulated as oral drops, Docolic is specifically designed for rapid administration and relief of abdominal pain and bloating in infants and young children.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Docolic.